TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.

Kim R M Blenman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.